SEC Company Response from Scopus BioPharma Inc. (SCPS) (CIK 0001772028) — Jan 31, 2020
Scopus BioPharma Inc. (SCPS) (CIK 0001772028)
Date: Jan. 31, 2020 · CIK: 0001772028 · Accession: 0001104659-20-009137
AI Filing Summary & Sentiment
File numbers found in text: 024-11137
Letter
Division of Corporate Finance Office of Life Sciences Securities and Exchange Commission File No.: 024-11137 Acceleration Request Requested Date: February 4, 2020 Requested Time: 2:30 PM Eastern Time
Dear Ms. Paik:
Scopus BioPharma Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Offering Statement on Form 1-A qualified at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Mark J. Wishner, who is an attorney with the Company’s outside legal counsel, Greenberg Traurig, LLP, to orally modify or withdraw this request for acceleration.
The Company hereby acknowledges that:
· should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing qualified, it does not foreclose the Commission from taking any action with respect to the to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing qualified does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Securities and Exchange Commission
January 31, 2020
Page 2
· the Company may not assert the staff comments and declaration of qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company also agrees that it will only sell its securities pursuant to the subject Offering Statement in states where the offering is registered or where there is an applicable exemption from a state’s registration requirements.
____________________________________
The Company requests that it be notified of such qualification by telephone call to Mark J. Wishner at (703) 749-1352 or email to him at: wishnerm@gtlaw.com.
Sincerely,
Scopus BioPharma Inc
Show Raw Text
CORRESP
1
filename1.htm
Scopus BioPharma Inc.
420 Lexington Avenue, Suite 300
New York, New York 10170
(212) 479-2513
January 31, 2020
Irene Paik
Division of Corporate Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re:
Scopus BioPharma Inc.
Amendment No. 1 to Offering Statement on Form 1-A
Filed: January 16, 2020
File No.: 024-11137
Acceleration Request
Requested Date:
February 4, 2020
Requested Time:
2:30 PM Eastern Time
Dear Ms. Paik:
Scopus BioPharma Inc. (the “Company”)
hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the
above-captioned Offering Statement on Form 1-A qualified at the “Requested Date” and “Requested Time” set
forth above or as soon thereafter as practicable.
The Company hereby authorizes Mark J. Wishner,
who is an attorney with the Company’s outside legal counsel, Greenberg Traurig, LLP, to orally modify or withdraw this request
for acceleration.
The Company hereby acknowledges that:
·
should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing qualified,
it does not foreclose the Commission from taking any action with respect to the to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing qualified does
not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Securities and Exchange Commission
January 31, 2020
Page 2
·
the Company may not assert the staff comments and declaration of qualification as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.
The Company also agrees that it will only
sell its securities pursuant to the subject Offering Statement in states where the offering is registered or where there is an
applicable exemption from a state’s registration requirements.
____________________________________
The Company requests that it be notified
of such qualification by telephone call to Mark J. Wishner at (703) 749-1352 or email to him at: wishnerm@gtlaw.com.
Sincerely,
Scopus BioPharma Inc
By: /s/ Morris C. Laster, M.D.
Name: Morris C. Laster, M.D.
Title: Co-Chairman and Chief Executive Officer